Literature DB >> 9230742

Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients.

E Deneuville1, C Perrot-Minot, F Pennaforte, M Roussey, J M Zahm, C Clavel, E Puchelle, S de Bentzmann.   

Abstract

We investigated the physicochemical and transport properties of sputum samples collected in physiotherapy from a well-documented group of 27 cystic fibrosis (CF) patients with identified CF genotypes. Sputum samples were characterized ex vivo for their water content, surface properties (surface tension and contact angle), rheologic properties (viscosity and elastic modulus), and transport properties (mucociliary and cough transport). These data were analyzed in relation to the clinical status of the patients (FEV1, FVC, Shwachman score, Brasfield score, nutritional status), their genotype, and the degree of infection of their sputa (leukocyte and Pseudomonas aeruginosa counts). We observed negative and significant correlations between mucociliary transport and elastic modulus of the patients' sputum (r = -0.63, p < 0.01), and between the cough transport and contact angle of the sputum (r = -0.81, p < 0.0001), respectively. The P. aeruginosa count was also significantly correlated with the sputum water content (r = -0.53, p < 0.02) as well as with the cough transport of the sputum (r = -0.62, p < 0.01). In CF patients with a sputum leukocyte count > 2,000/mm3, the sputum water content (p < 0.02), FEV1 (p < 0.05) and FVC (p < 0.02) were significantly lower than those of CF patients with a leukocyte count < or = 2,000/mm3. CF patients with a homozygous delta F 508 genotype had significantly greater values of sputum water content (p < 0.05), and cough-transport capacity (p < 0.05) than did heterozygous patients. No correlation was observed between the sputum properties and any of the clinical data. These results suggest that the control of infection should be emphasized in CF, since it can directly or indirectly modulate the degree of hydration, and therefore the physicochemical and transport properties, of airway secretions.

Entities:  

Mesh:

Year:  1997        PMID: 9230742     DOI: 10.1164/ajrccm.156.1.9606123

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

1.  Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.

Authors:  Urszula Wnorowska; Katarzyna Niemirowicz; Melissa Myint; Scott L Diamond; Marta Wróblewska; Paul B Savage; Paul A Janmey; Robert Bucki
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.

Authors:  Hirotoshi Matsui; Victoria E Wagner; David B Hill; Ute E Schwab; Troy D Rogers; Brian Button; Russell M Taylor; Richard Superfine; Michael Rubinstein; Barbara H Iglewski; Richard C Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation.

Authors:  M Corradi; P Pignatti; P Manini; R Andreoli; M Goldoni; M Poppa; G Moscato; B Balbi; A Mutti
Journal:  Eur Respir J       Date:  2004-12       Impact factor: 16.671

Review 4.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

Review 5.  Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway.

Authors:  Sophie Moreau-Marquis; Bruce A Stanton; George A O'Toole
Journal:  Pulm Pharmacol Ther       Date:  2008-01-29       Impact factor: 3.410

6.  Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.

Authors:  Sophie Moreau-Marquis; George A O'Toole; Bruce A Stanton
Journal:  Am J Respir Cell Mol Biol       Date:  2009-01-23       Impact factor: 6.914

7.  Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum.

Authors:  David J Serisier; Mary P Carroll; Janis K Shute; Simon A Young
Journal:  Respir Res       Date:  2009-07-06

Review 8.  Nanodelivery in airway diseases: challenges and therapeutic applications.

Authors:  Indrajit Roy; Neeraj Vij
Journal:  Nanomedicine       Date:  2009-07-16       Impact factor: 5.307

Review 9.  Extracellular barriers in respiratory gene therapy.

Authors:  Niek Sanders; Carsten Rudolph; Kevin Braeckmans; Stefaan C De Smedt; Joseph Demeester
Journal:  Adv Drug Deliv Rev       Date:  2008-12-24       Impact factor: 15.470

10.  Oscillating Positive Expiratory Pressure on Respiratory Resistance in Chronic Obstructive Pulmonary Disease With a Small Amount of Secretion: A Randomized Clinical Trial.

Authors:  Ada Clarice Gastaldi; Paolo Paredi; Anjana Talwar; Sally Meah; Peter J Barnes; Omar S Usmani
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.